Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer	Kidney-sparing; Nab-paclitaxel; PD-1 Inhibitor; Renal Pelvic Carcinoma; Tislelizumab	Recruiting	Phase 2	2025-11-18		NCT07233252

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Tianjin Medical University Second Hospital	50

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The Second Hospital of Tianjin Medical University	Tianjin	China	3

Clinical trials